{"id":170884,"date":"2023-08-29T23:26:21","date_gmt":"2023-08-30T04:26:21","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/08\/bluerocks-cell-therapy-shows-early-promise-in-parkinsons-study"},"modified":"2023-08-29T23:26:21","modified_gmt":"2023-08-30T04:26:21","slug":"bluerocks-cell-therapy-shows-early-promise-in-parkinsons-study","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/08\/bluerocks-cell-therapy-shows-early-promise-in-parkinsons-study","title":{"rendered":"BlueRock\u2019s cell therapy shows early promise in Parkinson\u2019s study"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/bluerocks-cell-therapy-shows-early-promise-in-parkinsons-study2.jpg\"><\/a><\/p>\n<p>Cell therapy company <a href=\"https:\/\/www.bluerocktx.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">BlueRock Therapeutics<\/a> has revealed promising results from the Phase 1 clinical trial of bemdaneprocel, an investigational stem cell therapy designed to treat Parkinson\u2019s disease. BlueRock, a wholly owned independently operated subsidiary of pharma giant Bayer, is creating a pipeline of cell therapy treatments for neurological, cardiovascular, immunological, and ophthalmic conditions.<\/p>\n<p>Bemdaneprocel is a stem cell therapy developed to replace dopamine-producing neurons that are lost in Parkinson\u2019s disease. Derived from pluripotent stem cells, the therapy involves implanting neuron precursors into the brains of patients to potentially restore neural networks and improve motor and non-motor functions.<\/p>\n<p>\u201cThe need for new therapies to help patients struggling with Parkinson\u2019s disease is clear,\u201d said Ahmed Enayetallah, Head of Development at BlueRock Therapeutics. \u201cWe are excited to be sharing the results of this Phase 1 and look forward to advancing bemdaneprocel to the next stage of clinical testing.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cell therapy company BlueRock Therapeutics has revealed promising results from the Phase 1 clinical trial of bemdaneprocel, an investigational stem cell therapy designed to treat Parkinson\u2019s disease. BlueRock, a wholly owned independently operated subsidiary of pharma giant Bayer, is creating a pipeline of cell therapy treatments for neurological, cardiovascular, immunological, and ophthalmic conditions. Bemdaneprocel is [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,6],"tags":[],"class_list":["post-170884","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-robotics-ai"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/170884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=170884"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/170884\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=170884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=170884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=170884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}